Keyphrases
Cost-effectiveness
100%
Economic Evaluation
85%
Cluster Randomized Trial
49%
Randomized Controlled Trial
47%
Physical Activity
36%
Weight Management Program
35%
Colorectal Cancer Screening
34%
Willingness to Pay
34%
Quality-adjusted Life Years
31%
Prevention Programs
29%
Clinical Efficacy
28%
Obesity
28%
Childhood Obesity
27%
Idiopathic Intracranial Hypertension
26%
Childhood Obesity Prevention
25%
Health Economics
23%
Bariatric Surgery
23%
Health-related Quality of Life
23%
Well-being
22%
Weight Control
22%
Quality of Life
21%
Steroid-resistant Nephrotic Syndrome
20%
Cultural Adaptation
18%
Dragon
18%
Child Weight
18%
Prednisolone
17%
Body Mass Index
17%
Menorrhagia
17%
Snacktivity™
17%
Trial Registration
17%
Decision Maker
16%
Vitamin D Deficiency
16%
Weight Loss
16%
Clinical Costs
15%
Primary School children
15%
Weight Management
15%
Ethnically Diverse
15%
Obesity Prevention
14%
Nephrotic Syndrome
14%
West Midlands
13%
Contingent Valuation
13%
BMI Z-score
13%
Enzyme Replacement Therapy
13%
Childhood Vaccination
13%
Review Evaluation
13%
Postnatal Women
13%
Upper Respiratory Tract Infection
13%
Prednisolone Treatment
13%
Chinese Primary School
13%
Immunization Programs
13%
Nursing and Health Professions
Cost Effectiveness Analysis
79%
Economic Evaluation
54%
Weight Management
49%
Childhood Obesity
38%
Quality Adjusted Life Year
35%
Systematic Review
32%
Quality of Life
27%
Idiopathic Intracranial Hypertension
26%
Bariatric Surgery
23%
Colorectal Carcinoma
21%
Diseases
20%
Obesity
18%
School-Aged Child
18%
Menorrhagia
17%
Nutrition Policy
15%
Health Care
15%
Sigmoidoscopy
14%
Construct Validity
14%
Body Mass
14%
Child Immunization
13%
Preventive Health Service
13%
Self Care
12%
Intracranial Pressure
10%
Cancer Screening
10%
Primary Medical Care
10%
Clinical Effectiveness
9%
Fabry Disease
8%
Enzyme Replacement Therapy
8%
Hurler Syndrome
8%
Prednisolone
8%
Nephrotic Syndrome
8%
Health Economics
8%
Convergent Validity
8%
Weight Loss Program
7%
Healthcare System
7%
Pediatric Quality of Life Inventory
7%
Incremental Cost-Effectiveness Ratio
6%
Screening
6%
Levonorgestrel Releasing Intrauterine System
6%
Economic Analysis
6%
Intention to Treat Analysis
6%
Drug Therapy
6%
Mass Screening
6%
Cost Benefit Analysis
5%
Confidence Interval
5%
Sample Size
5%
General Practitioner
5%
Hospital
5%
Population
5%